ASCO 2025靶病灶可持续缩减至完全缓解！全球首创肠癌CAR-T疗法客观缓解率达80%

Group 1 - The latest progress of the GCC19CART therapy for colorectal cancer was presented at the 2025 ASCO annual meeting by Dr. Benjamin L. Schlechter from Dana-Farber Cancer Institute [1] - The therapy has shown a high objective response rate (ORR) of 80% in a Phase I clinical trial involving 10 patients with metastatic colorectal cancer (mCRC) who had relapsed after standard second-line treatment [2] - One patient achieved complete response (CR) after 10 months, demonstrating the sustained efficacy of GCC19CART in treating advanced colorectal cancer [3] Group 2 - In previous clinical trials conducted in China, GCC19CART also exhibited positive treatment effects, with an ORR of 50% and significant survival benefits, including over 30% of responding patients surviving beyond 4 years [4] - The clinical trial results have been published in the prestigious journal JAMA Oncology, receiving international recognition and praise for the potential of GCC19CART as a new generation cancer therapy [4] - The company, Standex Biotech, focuses on developing CAR-T cell therapies for solid tumors and has received FDA approval for clinical trials of GCC19CART, which is currently ongoing in the U.S. [5]